预约演示

GSK, moving fast to buy Aiolos, pays $1B to challenge Amgen, AstraZeneca for asthma market

2024-01-09

交易

上市批准临床3期并购临床2期免疫疗法

GSK moved quickly to add the long-acting anti-TSLP antibody to its portfolio,

GSKl, that was fast. Seventy seven days aanti-TSLP antibodyunched to the public, GSK has disclosed a deal to buy the biotech and its phase 2 asthma treatment for $1 billion upfront and up to $400 million in regulatory milestones.

Aiolos broke cover in late October, launching Aiolos Bio5 million series A round GSKled by Atlas Venture, Bain Capital Life Sciences, Forbionasthmaofinnova Investments. The biotech raised the money to fund the development of a long-acting anti-TSLP monoclonal antibody, AIO-001, that it picked up from Jiangsu Hengrui Pharmaceuticals two months earlier.

Aioloscompanies got to the TSLP opportunity before GSK. Amgen and AstraZeneca won FDA approAtlas Ventureti-TSLP antibody, Tezspire, late in 2021. Sofinnova Investmentssale' sign on its midphase TSLP prospect, CSJ117, months after the FDA aanti-TSLP monoclonal antibody AIO-001 Jiangsu Hengrui Pharmaceuticals

GSK has weighed up the competition and bet up to $1GSKbiAmgen on AAstraZenecaa staFDAent, Tony Wood, canti-TSLP antibodyfiTezspireSK, called AIO-0Novartisentially best-in-class medicine that could expand the cCSJ117’s biologics portfoFDA to the 40% Tezspiree asthma patients with low T2 inflammation.

GSKt-hoc analyses of phase 2/3 trials of Tezspire linked the antiAIO-001 reductions in exacerbations in T2 low asthmas, a subgrouGSKhat otherAIO-001 including GSK’s Nucala and phase 3 prospect depemokimab, aren’t designed to treat. Tezspire’s broad efficacy lasthma FDA to make itlow T2 inflammationrug approved for severe asthma without phenotypic limitations, such as eosinophilic, or biomarker restrictions.

The belief that AIO-001 can improve on TeTezspireests, in part, on its dosing schedule. Tezspire is given subcuasthmasly once a month. GSK believes the “enhanced potNucaland half-life extensiondepemokimab” of AIO-001 could support dTezspireery six months. The Big PhFDAa’s work on the HIV drasthmabenuva and Apretude has shasthmaw longer-lasting medicines can win market share.

GSK, which will AIO-001 rights to AIO-0Tezspirede of Greater China, plans to run a phaseTezspire in adults with asthma and is assessingGSKether to expand development into other indications, including chronic rAIO-001usitis with nasal polyps. Amgen and AstraZeneca are running phase 3 trials of TCabenuvain peApretudeh chronic rhinosinusitis and eosinophilic esophagitis.

GSK deal represents another succesAIO-001it for Aiolos CEO Khurem Farooq, who co-founded the biotech with Tony Aasthma M.D., after leading Gyroscope Therapeutics to an $800 million takeover by Novartichronic rhinosinusitis nasal polyps Amgen AstraZeneca Tezspire chronic rhinosinusitis eosinophilic esophagitis

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构